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James C Sacchettini6, Hunmin Jung6, Wee Lin Wong7, Lee Fah Yap7, Yun Fong Ngeow5, 
Ian C Paterson7 & Hao Wang2
It is an urgent need to develop new drugs for Mycobacterium tuberculosis (Mtb), and the enzyme, 
dihydrofolate reductase (DHFR) is a recognised drug target. The crystal structures of methotrexate 
binding to mt- and h-DHFR separately indicate that the glycerol (GOL) binding site is likely to be 
critical for the function of mt-DHFR selective inhibitors. We have used in silico methods to screen 
NCI small molecule database and a group of related compounds were obtained that inhibit mt-
DHFR activity and showed bactericidal effects against a test Mtb strain. The binding poses were 
then analysed and the influence of GOL binding site was studied by using molecular modelling. By 
comparing the chemical structures, 4 compounds that might be able to occupy the GOL binding 
site were identified. However, these compounds contain large hydrophobic side chains. As the GOL 
binding site is more hydrophilic, molecular modelling indicated that these compounds were failed to 
occupy the GOL site. The most potent inhibitor (compound 6) demonstrated limited selectivity for 
mt-DHFR, but did contain a novel central core (7H-pyrrolo[3,2-f]quinazoline-1,3-diamine), which may 
significantly expand the chemical space of novel mt-DHFR inhibitors. Collectively, these observations 
will inform future medicinal chemistry efforts to improve the selectivity of compounds against mt-
DHFR.
Tuberculosis (TB) is a deadly infectious disease caused by Mycobacterium tuberculosis (Mtb) that is par-
ticularly prevalent in South-East Asia and Africa. In 2013, it is estimated that 9 million people developed 
TB and 1.5 million died from the disease1. Despite the fact that death from TB is often preventable, the 
rapid increase of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis has resulted 
in an urgent need to develop new drug targets for Mtb2,3.
1School of Chemistry and Chemical Engineering, Beifang University of Nationalities, Yinchuan, 750021, P. R. China. 
2School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, P. R. China. 3School of Basic Medicine, Ningxia 
Medical University, Yinchuan, 750004, P. R. China. 4Key Laboratory of Fertility Preservation and Maintenance of 
Ministry of Education, Ningxia Medical University, Yinchuan, 750004, P.R. China. 5Department of Pre-Clinical 
Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Bandar Sungei Long, 43000, 
Malaysia. 6Department of Biochemistry and Biophysics, Texas A & M University, College Station, TX 77843, USA. 
7Department of Oral Biology and Biomedical Sciences and Oral Cancer Research and Coordinating Centre, Faculty 
of Dentistry, University of Malaya, Kuala Lumpur, 50603, Malaysia. Correspondence and requests for materials 
should be addressed to H.W. (email: paxhw@yahoo.co.uk)
Received: 14 July 2015
Accepted: 23 September 2015
Published: 16 October 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:15328 | DOi: 10.1038/srep15328
The enzyme, dihydrofolate reductase (DHFR), catalyzes NADPH-dependent reduction of dihydro-
folate to tetrahydrofolate, which is a precursor of cofactors necessary for the synthesis of thymidylate, 
purine nucleotides, methionine, serine, and glycine that are required for DNA, RNA, and protein syn-
thesis4,5. Specific inhibitors of mycobacterial DHFR (mt-DHFR) that are active against live Mtb cells 
have been developed, suggesting that such inhibitors may be useful for treating TB6. Highly potent inhi-
bition of DHFR has been achieved with analogues of the substrate, dihydrofolate, and one of the most 
well-known inhibitors is Methotrexate (MTX, Fig.  1), which binds to both human DHFR (h-DHFR) 
and mt-DHFR without any significant selectivity7,8. Such inhibitors contain 2,4-Diaminopteridin as the 
central core and are referred to as classical inhibitors. However, the full pteridinediamine structure is not 
required and non-classical inhibitors were subsequently developed that contain pyrimidine-2,4-diamines 
or analogues as the central cores, such as Trimethoprim (TMP)9, Pyrimethamine10,11, Methylbenzoprim12 
and Bromo-WR9921013,14 (Fig. 1).
Analysis of the crystal structures of MTX binding to mt- and h-DHFR indicate that mt-DHFR 
binds with MTX, glycerol (GOL) and NADPH (PDB ID: 1DF7) (Fig.  2)15, but the GOL binding site 
is essentially absent in h-DHFR (PDB ID: 1OHJ, h-DHFR complexed with NADPH and PT523)16. The 
mt-DHFR active site can be roughly divided into 2 parts, the dihydrofolate and GOL binding sites. 
Most DHFR inhibitors target the dihydrofolate binding site. The GOL binding site is a relative small 
pocket, and is very close to the dihydrofolate binding site, such that it might be treated as an extension 
of dihydrofolate binding site. It has been assumed that the GOL binding site is critical for the function 
of mt-DHFR selective inhibitors15,17. For example, El-Hamamsy et al., designed and synthesised a group 
of compounds containing GOL-like side chains, and among these compounds, compound El-7a (Fig. 1) 
showed notable selectivity for inhibition effects on mt-DHFR against h-DHFR17. However, the assay they 
used to evaluate the abilities of El-7a was based on TB5 Saccharomyces cerevisiae carrying the DHFR 
genes from M. tuberculosis and human. Therefore, there is no direct evidence to show El-7a can inhibit 
the growth of M. tuberculosis.
In the present study, pharmacophore models were built using in silico methods that considered the 
influence of the GOL binding site. A group of related compounds were obtained and tested for their 
ability to inhibit mt-DHFR activity and for the bactericidal effects against a test Mtb strain. Of these, a 
group of compounds that significantly inhibited the growth of Mtb (without strong selectivity against 
h-DHFR) were obtained. In order to understand the relatively low selectivity (5 times vs h-DHFR for 
the most potent compound), the influence of GOL binding site was studied using molecular dynamic 
simulations and free energy calculations, as it was believed that the GOL binding site could be important 
for the selectivity.
Figure 1. The known inhibitors of mt-DHFR. 
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Methods
Selection of Docking Libraries. The National Cancer Institute compounds library (NCI Release 4, 
265,242 compounds, published in May 2012) was chosen for computer screening. The 3D conformations 
of all the molecules were generated using the Sybyl (v 7.3; Tripos) virtual screening tools.
System Setup. The crystal structure of mt-DHFR in complex with NADPH, GOL and MTX (PDB 
ID: 1DF7)15 was taken as the receptor. The bound ligand, MTX, was extracted, and used as a reference 
to indicate the binding site. The receptor was treated with Amber 1218, not only for virtual screening and 
molecular docking, but also for subsequent molecular dynamic simulations. The parameters of NADPH 
were obtained from AMBER parameter database (http://www.pharmacy.manchester.ac.uk/bryce/amber/, 
uploaded by U. Ryde) and the ab initio QM calculations were performed on GOL using the B3LYP 
6-31G* basis set within Gaussian0919. The molecular geometries were optimised and the atom-centered 
point charges were calculated to fit the electrostatic potential using RESP20. The receptor was treated by 
leap module in Amber 12 with amber ff12SB (for the protein part) and Generalized Amber Force Field 
(GAFF, for the GOL part)21 force field, and then the receptor was saved in the pdb format for virtual 
screening and molecular docking.
Virtual screening. A total of 78 inhibitors of mt-DHFR were collected from the PDB (ligands 
complexed with protein) and various literature sources17,22–25. All these compounds were docked into 
mt-DHFR to understand their interactions with the protein. A 3D-pharmacophore model was then built 
and used to search the NCI database (National Cancer Institute small molecule database release 4) using 
the Unity module within Sybyl, as shown in Fig. 3A. As compound El-7a17 was predicted to occupy the 
GOL binding site which may cause the selectivity against h-DHFR, a decoy compound template was 
designed and used as a reference to perform a similarity search using vROCS (version 3.1.2, Openeye)26 
with default settings (Fig.  3B). In the molecule template, the acylamino side chain was used to mimic 
the hydrogen bond acceptors and donors on GOL.
Molecular Docking. FRED Docking. FRED (v 3.0.1; Fast Rigid Exhaustive Docking)27 is a 
protein-ligand docking program released by Openeye. The hits obtained from previous virtual screening 
were treated with the Omega2 (v 2.5.1.4)28 module in the Openeye package using the default settings 
to generate a multi-conformers molecular library, and saved at most 200 conformations per compound. 
The hits library was then docked to mt-DHFR using FRED with default settings, and ranked by the 
Chemgauss 4 scoring function. The top 500 compounds were recorded for further consideration.
GOLD Docking. GOLD (v 5.2.2 Genetic Optimization for Ligand Docking)29 was used to dock each 
ligand 10 times, starting each time from a different random population of ligand orientations and using 
the default automatic genetic algorithm parameter settings. All torsion angles in each compound were 
allowed to rotate freely and the results of the different docking runs were ranked using Gold Score. The 
top 500 molecules were considered for experimental testing.
Figure 2. The binding sites of MTX, GOL and NADPH in the crystal structure of mt-DHFR. 
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Generation of recombinant enzymes and in vitro assays for Mtb and human DHFR. Recom- 
binant DHFR enzymes were expressed and purified as described previously30. Enzyme assays were per-
formed in 100 mM HEPES, 50 mM KCl, pH 7.0 at 25 °C. The absorbance decrease at 340 nm representing 
the oxidation of NADPH was monitored with a spectrophotometer (Cary 50, Varian, Palo Alto, CA). 
Inhibitors were added to a 1 ml cuvette at various concentrations, with the individual DHFRs (20 nM), 
and 40 μ M of NADPH, and the reaction was initiated by the addition of 40 μ M of dihydrofolate. For 
IC50 determinations, 20 nM of DHFRs was incubated with 40 μ M of cofactor NADPH and seven serially 
diluted concentrations of the inhibitors for 1 minute. The reaction was initiated by the addition of 40 μ M 
dihydrofolate. The reaction progress was measured for 2 minutes, and the linear region was used to deter-
mine the initial velocity parameters. Percent inhibition values from different concentration points were 
analysed by the curve fitting program supported by the Collaborative Drug Discovery.
Microbroth culture for bacteriostatic and bactericidal activity. The anti-mycobacterial activity 
of the compounds was tested by the measurement of OD readings and agar plate cultures. The test strain 
used was a stock culture of M. tuberculosis H37Ra (ATCC 25177) stored at − 80 °C. Prior to testing, the 
stock culture was thawed and grown on Middlebrook 7H10 agar (Difco, USA) to check for viability and 
purity. To prepare the inoculum, a suspension of the culture in Middlebrook 7H9 broth (Difco, USA) 
was adjusted to a turbidity equivalent to McFarland standard no.1 and further diluted to a final concen-
tration of approximately 105 cfu/ml. The compounds were dissolved in DMSO and diluted in 1% DMSO 
in 7H9 broth to obtain 100 μ g/ml, 50 μ g/ml, 10 μ g/ml, 5 μ g/ml 1 μ g/ml and 0.1 μ g/ml of compound. 
Each dilution was pipetted in 150 μ l duplicates into a sterile 96-well microtitre plate. Three controls were 
set up with (a) 1% DMSO in 7H9 broth (b) 7H9 broth without DMSO and (c) p-amino salicylic acid 
(PAS) at 4 μ g/ml (26.12 μ M) in 7H9 broth with 1% DMSO. All wells were then inoculated with 10 μ l 
of the mycobacterial culture at 105 cfu/ml, sealed with parafilm and incubated at 36 °C for 28 days. OD 
readings (at 630 nm wavelength) were taken daily using TECAN spectrophotometer with Magellan soft-
ware version 7.1. In addition, on day 14 and day 28, 10 μ l was removed from each well for subculturing 
on compound-free 7H10 agar plates which were incubated up to six weeks at 36 °C. The number, size 
and time of appearance of colonies in each subculture was recorded. A random sample of colonies was 
stained for acid-fastness to exclude non-mycobacterial contamination. Bactericidal activity was indicated 
by no growth of the test strain in the subculture, up to six weeks of incubation. Compounds showing 
less increase in OD readings than the no-compound controls but positive growth in the subcultures were 
deemed to have bacteriostatic activity.
Molecular Dynamic Simulation. Each selected compound and mt-DHFR complex was explicitly 
solvated in a truncated octahedral box of TIP3P model water (at least 12 Å from the complex to avoid 
periodic artifacts from occurring) by using Amber 12 with the amber ff12SB force field. Enough Na+ 
ions were added to neutralize the charges of the system by using the “addions” command line within the 
tleap module (AmberTools 12, which adds counterions around the complex using a Coulombic potential 
on a grid). The whole system was first optimised by energy minimisation, followed by 40 ns molecular 
dynamic simulation. To obtain the parameters for the ligands and GOL, QM calculations were performed 
by using the B3LYP 6-31G* basis set within Gaussian09 to optimise molecular geometries, and the 
atom-centred point charges were calculated to fit the electrostatic potential using RESP. The parameters 
of NADPH were obtained from the AMBER parameter database, as described previously. GOL and 
each ligand were treated by GAFF for parameters. We used the Principal Component Analysis (PCA) 
approach to check for equilibration and sampling. At least the last 20 ns stable, equilibrated trajectories 
of each simulation were taken for energy analysis.
Figure 3. (A) 3D-Pharmacophore model generated by Sybyl, and MTX was aligned to the model to make it 
clear. (B) The decoy molecule created for vROCS search.
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The standard equilibration protocol used was as follows:
(1) The solvent was energy minimised by 50 steps of the steepest descent method and then followed by 
10000 steps of the conjugate gradient method with the default nonbonded cutoff of 8 Å, while the 
solute was held fixed.
(2) The entire system was energy minimised with the same settings as the previous step.
(3) The solvent was subjected to a short (20 ps) MD simulation at a temperature of 100 K, under constant 
pressure conditions. For this and all following simulations, MD simulations were performed with ex-
plicit solvent models and in the NPT ensemble (T = 300 K; P = 1 atm). Periodic boundary conditions 
(PBC) and particle-mesh-Ewald method (PME)31 were used to model long-range electrostatic effects, 
with the temperature coupled to an external bath using a weak coupling algorithm32. The cutoff 
non-bonded interaction was set as 8 Å. The bond interactions involving H-atoms were constrained 
by using the SHAKE algorithm.
(4) Over 20 ps, the solvent temperature was raised to 300 K. During both this phase and the last, po-
sition restraints on every solute atom (force constant 100 kcal/mol/Å2) maintained them in their 
energy-minimised conformation.
(5) Over a series of 20 ps constant–pressure simulations at 300 K, the restraints on the solute were grad-
ually relaxed (50, 25, 10, 5, 2, and then 1 kcal/mol/Å2).
(6) The final 200 ps MD simulations were performed as the equilibration runs without any restraints.
After the energy minimisation and equilibrations, production MD was run for 40 ns in an NPT 
ensemble at 1 atm and 300 K. The time step necessary to solve the Newton’s equations was chosen to be 
equal to 2 fs and the trajectory files were collected every 10 ps for the subsequent analysis. All trajectory 
analysis was performed with the Ptraj module in the AmberTools 12 and examined visually using VMD 
software33.
In the present work, in total 9 series of molecular simulations were performed, and they are: El-7a in 
complex with mt-DHFR in the absence (Pose 1 and 2) and in the presence (Pose 3) of GOL; compound 
2 in complex with mt-DHFR in the absence (Pose 1, 2 and 3) and in the presence (Pose 4) of GOL; 
compound 6 in complex with mt-DHFR and in complex with h-DHFR.
Binding Free Energy Calculations. The binding free energy can be calculated using equation 1 from 
a well-equilibrated molecular dynamics simulation:
∆ = − − ( )( ) ( ) ( )G G G G 1complex protein ligand
Where G is the average free energy calculated from a set of structures taken from the equilibrated 
simulation (snapshots). Two popular choices to calculate the binding free energy of the snapshots are 
the Poisson–Boltzman (PBSA) and generalised Born (GBSA) models34–38, where SA corresponds to an 
estimation of the non-polar solvation free energy based on a simple surface area term.
In the present study, one thousand snapshots collected from the last 20 ns stable simulations at 20 ps 
intervals were used, and MM-PBSA was chosen to calculate the binding free energies with the Python 
script, MMPBSA.py, included in AMBERTOOLS 13. The nonpolar solvation free energy (Δ Gnp) was 
determined by the solvent accessible surface area (SASA) according to equation 2.
∆ = γ + β ( )G SASA 2np
Where the surface tension γ and the offset β were set to the standard values of 0.00542 kcal/mol/Å2 and 
0.92 kcal/mol, respectively. Other options were set to default settings. The entropy was estimated by using 
the Normal Mode program within the AMBER suite. Because these calculations are computationally 
intensive, only 100 snapshots for each MD trajectories were used for the normal-mode analysis of the 
equilibrated structure.
In the present work, in total 8 series of binding free energy calculations were performed, and they 
are: El-7a in complex with mt-DHFR in the absence (Pose 1 and 2) of GOL; compound 2 in complex 
with mt-DHFR in the absence (Pose 1, 2 and 3) and in the presence (Pose 4) of GOL; and compound 6 
in complex with mt-DHFR and in complex with h-DHFR.
Results and Discussion
Virtual screening and Molecular Docking. The docking results were clustered by using Discovery 
Studio and then carefully analysed manually. After removal of duplicates and those molecules that have 
already been previously reported as mt-DHFR inhibitors, 213 compounds (158 molecules selected from 
the hit list based on vRocs searching, and 55 from Sybyl searching) were chosen from the final hit list. 
Following manual inspection with the combined aims of covering the maximum amount of chemi-
cal space while avoiding non drug-like function groups, 40 compounds (26 molecules based on vRocs 
searching, and 14 on Sybyl searching) were subsequently selected and ordered from NCI to test for their 
ability to inhibit mt-DHFR and h-DHFR.
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Inhibition of DHFR activities in vitro. The 40 compounds were tested for their ability to inhibit 
recombinant mt-DHFR and h-DHFR activity in in vitro enzyme assays. Eight compounds showed strong 
inhibition effects on mt-DHFR and three of these compounds (6, 7, and 8) were more potent inhibitors 
of mt-DHFR compared to h-DHFR (Table 1).
Compound
Compound concentration (μg/ml)
100 50 10 5 1 0.1
1 + + + + + + + + + + + + + + + + + + 
2 + + + + + + + + + + + + + + + + 
3 + + + + + + + + + + + + + + + 
4 — + + + + + + + + + + + + + + 
5 + + + + + + + + + + + + + + + + + + 
6 — — + + + + + + + + + + + 
7 + + + + + + + + + + + + + + + + + + 
8 — + + + + + + + + + + + + + + + 
PAS (4 μ g/ml) + + 
Table 2.  Anti-mycobacterial activity of compounds 1–8 against Mtb H37Ra, showing colony counts 
after four weeks of exposure to each compound. − no growth; + , 1–10 colonies; + + , 11–100 colonies; 
+ + + , colonies too numerous to count.
ID NSC-ID Structures IC50(nM) mt-DHFR IC50(nM) h-DHFR Ratio h-DHFR/mt-DHFR

















4 212061 2600 2500 0.96
5 343495 2800 230 0.08
6 339579 6 33 5.5
7 305778 63 440 6.98
8 305767 40 100 2.5
Table 1.  Structures and activity against recombinant mt- and h-DHFR.
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Antibacterial activity. In the microbroth cultures for the demonstration of mycobacterial inhibition, 
the 7H9 broth and 1% DMSO controls showed a steady increase in OD readings and yielded abundant 
growth of M. tuberculosis H37Ra colonies within 14 days of incubation on 7H10 agar. In the presence of 
para-aminosalicylic acid (PAS), one of the standard anti-TB drugs, there was only scanty growth plus a 
two-week delay in the appearance of colonies. These results are consistent with uninhibited mycobacte-
rial multiplication in 1% DMSO and a more than two-log reduction in growth in the presence of PAS. 
All eight compounds showed varying degrees of growth inhibition on the test strain, seen as total inhi-
bition of growth, reduction in colony counts, delayed appearance of colonies or slower increase in colony 
size. The final colony counts after four weeks of exposure to the compounds are shown in Table  2. At 
100μ g/ml, three compounds (4, 6 and 8) showed bactericidal activity. At 50 μ g/ml, only one (compound 
6) was still bactericidal, while at 10 μ g/ml, only compound 6 (at 25.37 μ M) showed a notable reduction 
in colony count. Compound 7 showed the least growth inhibition, affecting the colony size but not the 
colony count. After exposure to 50 μ g/ml of compound 8, the test strain did not grow in the 14-day 
subculture but formed abundant colonies in the 28-day subculture. This unexpected finding raised the 
possibility of induced resistance in which small numbers of mutants, when given a selective advantage 
in the presence of the compound, multiplied to become a predominantly resistant population. Overall, 
Figure 4. The alignment of compound El-7a in binding poses 1 and 2 in the system in the absence of 
GOL. The carbon atoms of compound El-7a in pose 1 are yellow, and those in pose 2 are shown in green. 
The GOL binding site is indicated in pink.
Figure 5. Compound El-7a in pose 1 (A) and in pose 2 (B). The hydrogen bonds are represented by green 
dotted lines.
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at 100 μ g/ml, compounds 4, 6 and 8 showed better activity than PAS; at 50 μ g/ml, compounds 2, 3 and 4 
showed similar activity as PAS; but at 10 μ g/ml, only compound 6 (25.37 μ M) retained the same activity 
as PAS (4 μ g/ml, 26.12 μ M).
Molecular Dynamic Simulation
The influence of GOL on the binding of compound El-7a. We were interested to examine the 
influence of GOL in the binding of potential mt-DHFR inhibitors because the GOL binding site is essen-
tially absent in h-DHFR (PDB ID: 1OHJ, h-DHFR complexed with NADPH and PT523)10. Therefore, 
the binding poses of compound El-7a were analysed in the absence or presence of GOL. In the absence 
of GOL, compound El-7a can be docked with two binding poses (Pose 1, the propanetriol group occu-
pied the GOL site; Pose 2, the propanetriol group pointed to the opposite direction of GOL site, Fig. 4). 
In the presence of GOL, compound El-7a could only be docked with one binding pose (pose 3) (both 
the propanetriol group and the benzene ring pointed to the opposite direction of GOL site). Molecular 
dynamic simulations, MM-PBSA and Normal Mode calculations were performed on these three binding 
poses to generate more detailed conformational and energy information.
In the absence of GOL, both pose 1 and pose 2 were stable. The average structures from the trajecto-
ries shown in Fig. 5 indicate that in pose 1 compound El-7a formed hydrogen bonds with Ile5, Asp27, 
Gln28, Leu24 and Tyr100, while in pose 2, it formed hydrogen bonds with Ile5 and Ile94. MM-PBSA 
and Normal Mode calculations were performed on these two simulations and the results showed the 
binding free energy of pose 1 was lower than that of pose 2, which indicated that pose 1 is a more stable 
binding pose (Table 3). This result suggests the propanetriol group of compound El-7a may occupy the 
GOL binding site. The free energy decomposition of MM-PBSA calculation was performed to analyze 
the interaction of El-7a with the active site in Pose 1. We observed that 6 residues showed strong con-
tributions to the binding free energy (lower than − 1.0 kcal/mol). They are Ile5 (− 1.61 Kcal/mol), Trp6 
(− 1.89 Kcal/mol), Ala7 (− 1.36 Kcal/mol), Ile20 (− 1.66 Kcal/mol), Trp22 (− 2.43 Kcal/mol) and Phe31 
(− 1.83 Kcal/mol). Among these residues, Ile5, Trp6, Ala7 and Phe31 show strong interactions with the 
Simulationns ∆Evdw ∆Eele ∆Gpb ∆Gnp ∆Ggas ∆Gsolv ∆Gmmpbsa T∆S ∆Gbinding
El-7a (Pose 1) − 41.28 ± 0.07 − 43.35 ± 0.14 59.64 ± 0.12 − 4.76 ± 0.003 − 84.63 ± 0.14 54.89 ± 0.12 − 29.74 ± 0.09 − 23.26 ± 1.20 − 6.48
El-7a (Pose 2) − 39.41 ± 0.06 − 15.80 ± 0.13 34.80 ± 0.11 − 5.22 ± 0.003 − 55.21 ± 0.13 29.59 ± 0.11 − 25.62 ± 0.07 − 22.05 ± 1.2 − 3.57
Table 3.  Binding free energies (Kcal/mol) of compound El-7a in Pose 1 and 2.
Figure 6. (A) The binding poses of compound El-7a and GOL at the beginning of simulation. (B) at 18 ns 
and (C) at 40 ns. To simplify the figures, NADPH is hidden.
www.nature.com/scientificreports/
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pyrimidine-2,4-diamines group, and Ile20 and Trp22 form interactions with the propanetriol group 
(GOL binding site). The major free energy contribution of Ile20 comes from the VDW interaction, whilst 
the major contributions of Trp22 are from both VDW (− 0.95 Kcal/mol) and electrostatic (− 2.41 Kcal/mol) 
interactions.
A simulation was performed on the system of mt-DHFR in complex with NADPH, GOL and El-7a. 
As shown in Fig. 6A, at the beginning of the simulation, GOL had strong interactions with its binding 
pocket (Trp22, Leu24, Asp27 and Glu28). With the simulations, compound El-7a slowly changed its ori-
entation; the propanetriol group of compound El-7a moved towards the GOL binding site. Asp27 grad-
ually moved close to the propanetriol group of compound El-7a and formed hydrogen bonds between 
them. During this process, GOL was slowly expelled from the binding site and left the protein complex 
(Fig. 6B). At the end of simulation, GOL moved out of the protein completely, and the propanetriol group 
of compound El-7a moved to the GOL binding site and formed hydrogen bonds with Asp27 and Leu24. 
The results of these simulations suggest that the GOL binding site could be a potential drug target. It 
must be addressed at here that the GOL is purely a crystallisation artifact, as mt-DHFR is usually stored 
with glycerol to maintain its activity. Therefore, GOL may affect the in vitro enzyme assays, but it unlikely 
can be a necessary co-factor for the mt-DHFR in a biologically relevant situation. The simulation with 
GOL was performed only for the reason to confirm El-7a has a strong ability to bind to GOL binding 
site, even when the binding site has been occupied by GOL.
Binding pose analyses of compounds 1–8. Based on previous simulation of compound El-7a, we 
asked whether compounds 1-8 identified in the present study could bind into the GOL binding site. By 
comparing the chemical structures of compounds 1–8 with compound El-7a, it was observed that only 
compounds 1, 2, 3 and 4 might cause a similar effect as compound El-7a because they contain side 
chains at 6 position on the pyrimidine-2,4-diamines. However, the side chain of compound 4 is much 
larger than the GOL binding site, which significantly reduces such a possibility. All eight compounds 
were docked again by GOLD in the absence of GOL and ten binding poses were saved for analysis. As 
we assumed, only compounds 1-3, were observed docking with dual binding poses. Among these three 
compounds, compound 2 showed the strongest inhibition effects on mt-DHFR, so it was selected for 
molecular dynamic simulations for more accurate binding pose analysis. In absence of GOL, compound 
Figure 7. The binding poses of compound 2. (A) Pose 1; (B) Pose 2; (C) Pose 3; (D) Pose 4.
www.nature.com/scientificreports/
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2 can be docked with three binding poses: Pose 1 (Fig.  7A), no side group binding to GOL binding 
site; Pose 2 (Fig. 7B), naphthalene ring binding to GOL binding site; and Pose3 (Fig. 7C), benzene ring 
binding to GOL binding site. In the presence of GOL, only one binding pose is available, which is similar 
to the pose 1, and we refer to this as Pose 4 (Fig. 7D). Molecular dynamic simulations, MM-PBSA and 
Normal Mode calculations were performed on these four binding poses for more detailed conforma-
tional and energy analysis.
Through the conformational analysis, we anticipated compound 2 cannot bind into the GOL binding 
site, because either the naphthalene ring or benzene ring is hydrophobic and cannot have strong inter-
actions with those hydrophilic residues at the GOL binding site. As shown in Table 4, in the absence of 
GOL, the binding pose 1 showed the lowest binding free energy in comparison with Pose 2 and Pose 3, 
which may indict compound 2 cannot occupy the GOL binding site, although the energy difference is 
not very significant. The free energy decomposition showed that in poses 2 and 3, although the naph-
thalene ring or benzene ring occupy the GOL binding site respectively, none of the key residues (Trp22, 
Leu24, Asp27 and Glu28) in the GOL binding site have significant free energy contributions (greater than 
− 1 Kcal/mol) for ligand binding. In the presence of GOL, the binding pose 4 shows a similar binding 
free energy with the consideration of entropy in comparison with the binding pose 1 in the absence of 
GOL. In binding pose 4, there are strong VDW interactions between GOL and compound 2, and the 
total free energy contribution is − 1.37 Kcal/mol, which is the 4th strongest contributions among all the 
residues, and GOL itself has a strong interaction with Trp22 (free energy contribution − 2.07 Kcal/mol). 
The results suggest that GOL functions as a bridge to link compound 2 and mt-DHFR, and by this way 
GOL enhances the enthalpy term of the binding free energy of the compound 2 in in vitro enzyme assays, 
but it also slightly increases the entropy penalties, so that the final binding free energies of compound 2 
in pose 1 and pose 4 are almost same. However, in the real biological situation as per the antibacterial 
activity assays, GOL is unlikely to be a cofactor binding in the GOL binding site, so that binding Pose 1 
may be the favourable binding pose in this case. Most DHFR inhibitors target the dihydrofolate binding 
site. The GOL binding site is a relatively small pocket that is very close to the dihydrofolate binding site 
and may be treated as an extension of the dihydrofolate binding site. The dihydrofolate binding site is 
relative large, so although those compounds with large hydrophobic side chains, such as compound 2, 
cannot occupy the GOL binding site, it can still fit into the dihydrofolate binding site. Once they bind 
into this site, the reduction of dihydrofolate to tetrahydrofolate can be prevented leading to the inhibition 
of Mtb growth.
The binding pose of compound 6. In the present study, as compound 6 was the most potent inhib-
itor of mt-DHFR and exhibited the strongest bactericidal activity, we analysed its binding pose in more 
Compound 2 ∆Evdw ∆Eele ∆Gpb ∆Gnp ∆Ggas ∆Gsolv ∆Gmmpbsa T∆S ∆Gbinding
Pose 1 − 47.77 ± 0.09 − 15.62 ± 0.09 37.41 ± 0.13 − 5.43 ± 0.005 − 63.39 ± 0.12 31.98 ± 0.13 − 31.41 ± 0.11 − 21.45 ± 1.46 − 9.96
Pose 2 − 48.05 ± 0.06 − 14.50 ± 0.07 37.51 ± 0.09 − 5.54 ± 0.003 − 62.55 ± 0.08 31.97 ± 0.09 − 30.58 ± 0.09 − 22.07 ± 1.08 − 8.51
Pose 3 − 45.47 ± 0.10 − 21.28 ± 0.08 42.98 ± 0.18 − 5.56 ± 0.004 − 66.75 ± 0.15 37.41 ± 0.18 − 29.34 ± 0.10 − 21.79 ± 1.24 − 7.55
Pose 4 − 48.22 ± 0.07 − 11.89 ± 0.07 32.33 ± 0.08 − 5.34 ± 0.005 − 60.11 ± 0.09 26.99 ± 0.08 − 33.13 ± 0.08 − 23.55 ± 1.05 − 9.58
Table 4.  Binding free energies (Kcal/mol) of compound 2 in Poses 1, 2, 3 and 4.
Figure 8. The binding pose of compound 6 in the absence of GOL. 
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detail. Compound 6 was docked in the presence and absence of GOL and this showed no significant 
differences between these two binding poses. The binding pose of compound 6 is similar to the bound 
MTX in the crystal structure. Figure  8 shows the results of the docking study in the absence of GOL, 
with the blue dotted area representing the binding site of MTX (or dihydrofolate) and the purple dotted 
indicating the binding site of GOL. As predicted, compound 6 occupies the MTX binding site without 
touching GOL binding site. In this binding pose, it can be observed from the docking results that com-
pound 6 formed 5 hydrogen bonds with Gln28, Asp27, Ile5, Tyr100 and Ile94, and it also formed strong 
hydrophobic interaction with Pro51 and Phe31.
The binding poses of compound 6 bound with mt-DHFR and h-DHFR were compared. It was 
observed that the binding pockets of these two proteins are highly conserved, and the binding poses 
of compound 6 are almost identical (Fig.  9), which is consistent with the fact that compound 6 only 
shows a very slight degree of selectivity against h-DHFR. DHFR inhibitors usually contain a central 
core of 2,4-diaminopteridin (classical inhibitors) or pyrimidine-2,4-diamines (non-classical inhibitors). 
However, compound 6 contains a novel central core (7H-pyrrolo[3,2-f]quinazoline-1,3-diamine), which 
will significantly expand the chemical space of novel DHFR inhibitors.
Molecular dynamic simulations were performed on compound 6 in complex with h-DHFR and 
mt-DHFR in the absence of bound GOL, as GOL is not a cofactor in the real biological situation. Through 
the conformation analyses along both trajectories, compound 6 was tightly bound to both proteins, and 
the binding poses were stable along the entire simulations. The MM-PBSA and Normal Mode calcula-
tions were performed on both systems, and it was found that the binding free energies of these two sim-
ulations were similar (Table 5), but the one with h-DHFR is slightly lower than that of mt-DHFR (only 
about − 0.76 Kcal/mol), which does not fully match the experimental data. The reason for this is likely 
to be a result of system error, because such small differences in binding affinities cannot be accurately 
Figure 9. The binding poses and interactions of compound 6 with (A) mt-DHFR and (A) h-DHFR. The key 
interactions (free energy contribution lower than –1 Kcal/mol) between compound 6 and (C) mt-DHFR, and 
(D) h-DHFR.
Compound 6 ∆Evdw ∆Eele ∆Gpb ∆Gnp ∆Ggas ∆Gsolv ∆G-mmpbsa T∆S ∆Gbinding
mt-DHFR − 45.69 ± 0.05 − 14.05 ± 0.08 35.72 ± 0.09 − 5.18 ± 0.003 − 59.73 ± 0.10 30.54 ± 0.09 − 29.19 ± 0.07 − 23.55 ± 1.23 − 5.64
h-DHFR − 46.76 ± 0.06 − 15.34 ± 0.10 38.64 ± 0.11 − 5.11 ± 0.002 − 62.10 ± 0.11 33.52 ± 0.11 − 28.58 ± 0.08 − 22.18 ± 1.20 − 6.40
Table 5.  Binding free energies (Kcal/mol) of compound 6 in mt-DHFR and h-DHFR.
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predicted by MM-PBSA and Normal Mode calculations, especially when the receptors are two different 
proteins. We also observed that the binding free energy of compound 2 with mt-DHFR is lower than 
that of compound 6, which contradicts the experimental data, most likely because the MM-PBSA and 
Normal Mode approaches are better at selecting poses for one compound than ranking molecules with 
significantly different structures (which is certainly true for compounds 2 and 6).
A free energy decomposition of MM-PBSA calculation was performed to analyze the interaction of com-
pound 6 with both mt-DHFR and h-DHFR. We observed that 4 residues contributed strongly to the bind-
ing free energy of compound 6 with mt-DHFR (lower than − 1.0 Kcal/mol). They are Ile5 (− 1.56 Kcal/mol), 
Trp6 (− 1.61 Kcal/mol), Phe31 (− 2.32 Kcal/mol) and Leu50(− 1.02 Kcal/mol). Among these residues, 
Ile5 (− 1.35 Kcal/mol VDW, − 1.73 Kcal/mol electrostatic interactions) and Trp6 (− 1.19 Kcal/mol VDW, 
− 0.94 Kcal/mol electrostatic interactions) show both VDW and electrostatic interactions, and Phe31 
and Leu50 mainly show strong VDW interaction. In the interactions between h-DHFR and compound 
6, there are five residues (Ile7 (− 1.74 Kcal/mol), Val8 (− 1.54 Kcal/mol), Phe31 (− 1.10 Kcal/mol), Phe34 
(− 2.34 Kcal/mol) and Ile60 (− 1.50 Kcal/mol) that demonstrated strong free energy contributions 
(lower than − 1.0 Kcal/mol). Among them, only Ile7 show free energy contributions from both VDW 
(− 1.33 Kcal/mol) and electrostatic interactions (− 1.72 Kcal/mol), and the remaining residues mainly 
contribute to the binding free energy via VDW interactions. The hydrophobic residue Phe31 in h-DHFR 
showed a strong free energy contribution, but the corresponding residue in Mt-DHFR, Gln28 (with a 
polar side chain, labeled in red in Fig. 9c), only showed a weak free energy contribution (− 0.37 Kcal/mol). 
This difference could be a potential direction for future molecular design attempts to improve the selec-
tivity of compound 6 analogues, for example by adding more polar groups at the corresponding position. 
Another more obvious direction is the addition of a GOL like group on compound 6 to occupy the GOL 
binding site.
Conclusion
Using in silico methods, we have identified a set of mt-DHFR inhibitors that inhibited recombinant 
mt-DHFR and h-DHFR to varying degrees and that showed bactericidal effects against M. tuberculo-
sis H37Ra. Molecular simulations indicated that the GOL binding site can be occupied by inhibitors 
containing appropriate side chains. Among the compounds identified in the present study, only the 
compounds 1, 2, 3 and 4 have such possibility. However, they all contain large hydrophobic side chains 
at 6 position on the pyrimidine-2,4-diamines. As the GOL binding site is more hydrophilic, and con-
tains hydrogen bond acceptors and donors, these compounds failed to occupy the GOL site, which 
could be one of the reasons that the present inhibitors did not show strong selectivity against h-DHFR. 
Compound 6 was the most potent inhibitor obtained in the present study. It contains a novel central 
core (7H-pyrrolo[3,2-f]quinazoline-1,3-diamine), which will significantly expand the chemical space of 
novel DHFR inhibitors. This compound did show a small degree of selectivity against h-DHFR and can 
be used as a lead compound for further optimization and will inform future medicinal chemistry efforts 
to improve the selectivity of compounds against mt-DHFR.
Whilst the GOL binding site is not essential for mt-DHFR enzyme activity, it is thought to be impor-
tant for the selectivity for mt-DHFR against h-DHFR. Our modelling study suggests hydrophilic side 
groups may be able to occupy this binding site. This approach may lead to new inhibitors being discov-
ered that specifically bind to mt-DHFR. However, it is cautionary to note that as Mtb has a thick cell 
wall that only allows highly hydrophobic compounds to pass through, adding a hydrophilic side group 
to compounds may prevent them from crossing the mycobacterial cell wall. Consequently, although such 
compounds may be able to specifically inhibit mt-DHFR, they may not be able to act on Mtb whole 
cells. Therefore, finding a balance between selectivity and activity on Mtb remains a major challenge in 
anti-TB drug discovery.
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